According to Zhitong Finance App, Jingtai Holdings (02228.HK) announced that LCC Technologies Ltd. (LCC Technologies), a wholly-owned subsidiary of the company, and the Stanford University Board of Governors have signed a drug discovery cooperation agreement. The collaboration combines Stanford University's disease biology research with LCC Technologies' automated and AI-driven small molecule drug discovery platform to accelerate and drive the development of new drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.